

Lucian R Chiriac

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4494483/publications.pdf>

Version: 2024-02-01

43
papers

7,053
citations

201385

27
h-index

276539

41
g-index

43
all docs

43
docs citations

43
times ranked

9710
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. <i>Journal of Pathology</i> , 2021, 253, 68-79.	2.1	25
2	Association of RERG Expression with Female Survival Advantage in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 565.	1.7	3
3	The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. <i>Pathology</i> , 2021, 53, 446-453.	0.3	25
4	Deep-learning based classification distinguishes sarcomatoid malignant mesotheliomas from benign spindle cell mesothelial proliferations. <i>Modern Pathology</i> , 2021, 34, 2028-2035.	2.9	8
5	Molecular characterization of localized pleural mesothelioma. <i>Modern Pathology</i> , 2020, 33, 271-280.	2.9	22
6	Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. <i>Modern Pathology</i> , 2020, 33, 281-296.	2.9	33
7	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	0.5	106
8	Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 288-292.	2.1	7
9	Pathology of Malignant Pleural Mesothelioma. <i>Thoracic Surgery Clinics</i> , 2020, 30, 367-382.	0.4	8
10	Molecular characterization of diffuse malignant peritoneal mesothelioma. <i>Modern Pathology</i> , 2020, 33, 2269-2279.	2.9	34
11	Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1037-1053.	0.5	40
12	Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. <i>Cancer</i> , 2019, 125, 4164-4171.	2.0	30
13	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	0.5	68
14	When You Hear Hoofbeats, Look for Horses, Not Zebras—Reply. <i>JAMA Oncology</i> , 2018, 4, 1011.	3.4	0
15	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 205-217.	0.5	33
16	Long-term outcomes after near-infrared sentinel lymph node mapping in non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1280-1291.	0.4	32
17	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 89-108.	1.2	461
18	Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. <i>Modern Pathology</i> , 2018, 31, 122-131.	2.9	32

#	ARTICLE	IF	CITATIONS
19	Identification of <i>ALK</i> Rearrangements in Malignant Peritoneal Mesothelioma. JAMA Oncology, 2018, 4, 235.	3.4	95
20	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery, 2018, 8, 1548-1565.	7.7	422
21	The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Human Pathology, 2017, 67, 160-168.	1.1	50
22	Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2017, 35, 8555-8555.	0.8	10
23	Ki-67 expression in pulmonary tumors. Translational Lung Cancer Research, 2016, 5, 547-551.	1.3	21
24	Tumor cell proliferation, proliferative index and mitotic count in lung cancer. Translational Lung Cancer Research, 2016, 5, 554-556.	1.3	4
25	NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 825-836.	2.3	75
26	Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature Genetics, 2016, 48, 407-416.	9.4	730
27	Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Research, 2016, 76, 319-328.	0.4	73
28	The 2015 World Health Organization Classification of Lung Tumors. Journal of Thoracic Oncology, 2015, 10, 1243-1260.	0.5	3,313
29	Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10299-10304.	3.3	77
30	Clinicopathologic Characteristics of Malignant Mesotheliomas Arising in Patients With a History of Radiation for Hodgkin and Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 4544-4549.	0.8	47
31	<i>p16</i> Deletion in Sarcomatoid Tumors of the Lung and Pleura. Archives of Pathology and Laboratory Medicine, 2013, 137, 632-636.	1.2	36
32	Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group. Archives of Pathology and Laboratory Medicine, 2013, 137, 647-667.	1.2	422
33	Emerging Targeted Therapies in Cancer. Archives of Pathology and Laboratory Medicine, 2012, 136, 474-475.	1.2	1
34	Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. European Journal of Cardio-thoracic Surgery, 2011, 40, 298-303.	0.6	44
35	Spiral Tissue Microarrays as Next Evolutionary Step in the High-density Tissue Microarray Technology. Nature Precedings, 2010, , .	0.1	0
36	Targeted Therapies in Lung Cancer. Surgical Pathology Clinics, 2010, 3, 71-82.	0.7	33

#	ARTICLE	IF	CITATIONS
37	Pathologic Evaluation of Malignant Pleural Mesothelioma. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2009, 21, 121-124.	0.4	23
38	Characterization of the myxoid variant of hibernoma. <i>Annals of Diagnostic Pathology</i> , 2006, 10, 104-106.	0.6	22
39	Epithelioid hemangioendothelioma in a patient with unusual involvement of the rib and intercostal lymph nodes. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 1488-1489.	0.4	10
40	Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. <i>Cancer</i> , 2006, 107, 2237-2244.	2.0	29
41	Phenotype of Microsatellite-Stable Colorectal Carcinomas With CpG Island Methylation. <i>American Journal of Surgical Pathology</i> , 2005, 29, 429-436.	2.1	63
42	Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. <i>Cancer</i> , 2005, 103, 1347-1355.	2.0	413
43	Signet-Ring Cell or Mucinous Histology after Preoperative Chemoradiation and Survival in Patients with Esophageal or Esophagogastric Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 2229-2236.	3.2	73